Arab Drug Company for Pharmaceuticals and Chemical Industries Reports EGP 160.93 Million in Net Profit After Tax During the First Seven Months of the Current Fiscal Year

Arab Drug Company for Pharmaceuticals and Chemical Industries announced that it recorded net profit after tax of EGP 160.93 million during the first seven months of the current fiscal year (from July through the end of January 2026), representing an annual growth of approximately 22.7% compared to the same period last fiscal year, when the company posted profits of EGP 131.15 million.

📈 Financial Performance Highlights for the Seven-Month Period:

• Net profit after tax: EGP 160.93 million.

• Annual growth rate: +22.7%.

• Total sales: EGP 803.88 million, compared to EGP 666.67 million in the corresponding period, reflecting improved sales performance and stronger operational support for the company’s activities.

📊 This growth comes amid the positive performance of Egypt’s pharmaceutical sector, as drug manufacturers continue to achieve stronger financial results driven by rising product demand and expanded distribution channels.